The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications.

Zhang Y, Zhang Z. · 2020

Read The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. by Zhang Y, Zhang Z. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7395159.txt.

Introduction

Zhang and Zhang review the history and advances of cancer immunotherapy in Cellular and Molecular Immunology. Immunotherapy has revolutionized treatment, with cell transfers and checkpoint drugs winning durable responses. Yet only some patients benefit, and the tumor's immune neighborhood helps decide who.

Immune cells inside a tumor shape its growth and the patient's outcome. That neighborhood is mixed and ever-changing, which long blocked precise analysis. Single-cell sequencing and mass cytometry now let researchers interrogate it systematically, exposing how cancer evades immunity. The two authors outline progress cell type by cell type, and the treatment ideas that follow. Readers get both a history and a field guide to the tumor microenvironment.

Catalog record

CREATORZhang Y, Zhang Z.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE103 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7395159

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications By Yuanyuan Zhang, Zemin Zhang Published in: Cellular and Molecular Immunology DOI: 10.1038/s41423-020-0488-6 ABSTRACT Immunotherapy has revolutionized cancer treatment and rejuvenated the field of tumor immunology. Several types of immunotherapy, including adoptive cell transfer (ACT) and immune checkpoint inhibitors (ICIs), have obtained durable clinical responses, but their efficacies vary, and only subsets of cancer patients can benefit from them. Immune infiltrates in the tumor microenvironment (TME) have been shown to play a key role in tumor development and will affect the clinical outcomes of cancer patients. Comprehensive profiling of tumor-infiltrating immune cells would shed light on the mechanisms of cancer–immune evasion, thus providing opportunities for the development of novel therapeutic strategies. However, the highly heterogeneous and dynamic nature of the TME impedes the precise dissection of intratumoral immune cells. With recent advances in single-cell technologies such as single-cell RNA sequencing (scRNA-seq) and mass cytometry, systematic interrogation of the TME is feasible and will provide insights into the functional diversities of tumor-infiltrating immune cells. In this review, we outline the recent progress in cancer immunotherapy, particularly by focusing on landmark studies and the recent single-cell characterization of tumor-associated immune cells, and we summarize the phenotypic diversities of intratumoral immune cells and their connections with cancer immunotherapy. We believe such a review could strengthen our understanding of the progress in cancer immunotherapy, facilitate the elucidation of immune cell modulation in tumor progression, and thus guide the development of novel immunotherapies for cancer treatment. INTRODUCTION Cancer is a disease of the genome, and it is characterized by a genomic instability in which numerous point mutations accumulate and structural alterations occur in the process of tumor progression.1,2 Such genomic variations could give rise to tumor antigens, which could be recognized by the immune system as nonself and elicit cellular immune responses.3,4 The immune system plays an essential role in immunosurveillance,4,5 as immune cells of the adaptive and innate immune systems infiltrate into the tumor microenvironment (TME) and contribute to the modulation of tumor progression.6,7 Innate immune cells, composed of natural killer (NK) cells, eosinophils, basophils, and phagocytic cells, including mast cells, neutrophils, monocytes, macrophages, and dendritic cells (DCs), participate in tumor suppression either by directly killing tumor cells or by triggering adaptive immune responses.8–10 The adaptive immune system functions with lymphocytes, including B cells and T cells, among which B cells play a major role in humoral immune responses, whereas T cells are involved in cell-mediated immune responses.5,11,12 Effective immune responses could either eradicate malignant cells or impair their phenotypes and functions.3 However, cancer cells have evolved multiple mechanisms, such as defects in antigen presentation machinery, the upregulation of negative regulatory pathways, and the recruitment of immunosuppressive cell populations,13–17 to escape immune surveillance, resulting in the impeded effector function of immune cells and the abrogation of antitumor immune responses. Immunotherapy, aiming to boost natural defenses to eliminate malignant cells, is a monumental breakthrough for cancer treatment and has revolutionized the field of oncology. Although the idea of unleashing the host immune system to eradicate cancer could trace back to a century ago,18,19 significant advances have been achieved in recent basic and clinical investigations. Multiple cancer types have shown sustained clinical responses to immunotherapy,20–25 albeit with limited response rates and unclear underlying mechanisms.26 Immune cells are the cellular underpinnings of immunotherapy; thus, understanding the immune infiltrates in the TME is the key to improving responsive rates and developing new therapeutic strategies for cancer treatment with immunotherapy. Although the tumor–immune ecosystem is highly complex and comprises a heterogeneous collection of cells, single-cell technologies have emerged as powerful tools for the dissection of the TME.27 Although tremendous efforts have been devoted to T-cell characterizations, other immune cells of the innate and adaptive immune systems, including DCs, macrophages, NK cells, and B cells, have also been shown to contribute to tumor progression and immunotherapy responses. In this review, we will outline the major categories of cancer immunotherapy and the history of their development, as well as the recent findings on tumor-infiltrating immune cells in human cancers, their connections with immunotherapy and potential clinical applications. THE RISE OF MAJOR CATEGORIES OF IMMUNOTHERAPY Here, we briefly review the historical studies that led to the development of several major types of immunotherapy applied in cancer treatment (Fig. 1).Fig. 1The major categories of immunotherapy. Different forms of cancer immunotherapy, including oncolytic virus therapies, cancer vaccines, cytokine therapies, adoptive cell transfer, and immune checkpoint inhibitors, have evolved and shown promise in clinical practice. The basic principles of each strategy and the corresponding cellular and molecular underpinnings involved in each step are depicted. DCs dendritic cells, NK natural killer, TCR T-cell receptor, CAT-T chimeric antigen receptor T-cell Oncolytic virus therapies For more than a century, traditional immunotherapy has approached cancer by harnessing bacterial or viral infection to enhance immune responses. As early as 1863, Virchow first discovered the connection between tumors and inflammation after observing that neoplastic tissues were often decorated with leukocytes of the immune system.28 The earliest case of cancer immunotherapy can be traced back to 1891, when William Coley, the father of immunotherapy, first attempted to leverage the immune system to treat cancer after noticing that mixtures of live and inactivated Streptococcus pyogenes and Serratia marcescens could cause tumor regression in sarcoma patients.29,30 Although such a pioneering strategy provided a proof of concept for treating cancer by the utilization of the immune system, the unknown mechanisms of action and the potential infection risks hindered its further progress. Decades later, oncolytic virus therapies were invented, which leverage genetically modified viruses to infect tumor cells, and thus stimulate a proinflammatory environment to augment systemic antitumor immunity.31,32 With advances in genetic engineering and virus transformation technologies, oncolytic virus therapies have made much progress in recent years. In particular, talimogene laherparepvec (T-Vec), also known as Imlygic, a genetically modified herpes simplex virus, demonstrates impressive clinical benefits for patients with advanced melanoma and has been approved for the treatment of unresectable metastatic melanoma.33 Cancer vaccines Cancer vaccines utilize tumor-specific antigens to trigger T-cell-mediated antitumor immune responses. Pivotal studies came from the identification of MZ2-E and MZ2-D, both of which are melanoma-derived antigens encoded by the MAGE (melanoma-associated antigen) gene family that could be recognized by cytotoxic T cells to trigger antitumor immune responses.34,35 Simultaneously, another human melanoma antigen, gpl00, was proven to be associated with tumor rejection in vivo by inducing immune responses mediated by tumor-infiltrating lymphocytes (TILs) in melanoma patients.36 These findings paved the way for utilizing tumor antigens as vaccines in cancer immunotherapy. Aside from tumor antigens, DC-based vaccination also showed significant clinical outcomes. DCs are the best equipped antigen-presenting cells (APCs) and play critical roles in eliciting antitumor immunity.37 Specifically, after activation by tumor antigens, DCs can internalize, process, and subsequently present the processed epitopes to T cells and induce cytotoxic T lymphocyte (CTL) immune responses.37 Due to their proficiency at antigen presentation, DCs are leveraged in DC-based vaccines, which involve the reinfusion of isolated DCs pulsed with tumor antigens or tumor cell lysates and stimulated with a defined maturation cocktail ex vivo.38 One representative example is sipuleucel-T, a DC-based immunotherapy that has been approved

Read the complete text